Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL839423 | 0.98 | CA1 (0.48) | CA1CA2CA9KMT2AALOX15 | |
| SCHEMBL17830372 | 0.82 | ALDH1A1 (0.50) | CA1CA2CA9KMT2AALOX15 | |
| Tert-Butyl Formate SCHEMBL27715080 | 0.80 | NPSR1 (0.40) | CA1CA2CA9KMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL966894 | 0.80 | ALDH1A1 (0.48) | CA1CA2CA9KMT2AALOX15 | |
| SCHEMBL1302726 | 0.79 | NPSR1 (0.44) | CA1CA2CA9KMT2AALOX15 | |
| SCHEMBL9835493 | 0.79 | KMT2A (0.44) | KMT2AALOX15TDO2POLBMAPK1 | |
| SCHEMBL31083477 | 0.77 | KMT2A (0.42) | KMT2AALOX15POLBMAPK1PYGL | |
| SCHEMBL11415204 | 0.77 | KMT2A (0.46) | KMT2AALOX15POLBPYGLNPSR1 | |
| SCHEMBL2586234 | 0.77 | KMT2A (0.42) | KMT2AALOX15POLBMAPK1PYGL | |
| SCHEMBL13969381 | 0.77 | KMT2A (0.42) | KMT2AALOX15POLBMAPK1PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115124441-B | Preparation method of No Bo Suan hydrazide compound, product and application thereof | 南京林业大学 | 2024-04-02 | — | — | CN | claimed |
| CN-117402076-A | Preparation method of norbornenyl acid formylhydrazine compound, product and application thereof | 南京林业大学 | 2024-01-16 | — | — | CN | claimed |
| CN-115124441-A | Preparation method of nopyl acid hydrazide compounds, nopyl acid hydrazide compounds and application of nopyl acid hydrazide compounds | 南京林业大学 | 2022-09-30 | — | — | CN | claimed |
| US-RE50878-E1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-05 | — | — | US | disclosed |
| WO-2025243042-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILIN D | THE UNIVERSITY OF LIVERPOOL (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-18 | — | — | US | disclosed |
| CN-115124441-B | Preparation method of No Bo Suan hydrazide compound, product and application thereof | 南京林业大学 | 2024-04-02 | — | — | CN | disclosed |
| EP-4339192-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of the University of California (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117402076-A | Preparation method of norbornenyl acid formylhydrazine compound, product and application thereof | 南京林业大学 | 2024-01-16 | — | — | CN | disclosed |
| EP-3478284-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-18 | — | — | US | disclosed |
| EP-2149552-A1 | 5,6 substituted benzamide derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | disclosed |
| US-7622492-B2 | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622492-B2 | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| CN-101573339-A | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation | GLENMARK PHARMACEUTICALS SA (CH) | 2009-11-04 | — | — | CN | disclosed |
| US-7297704-B2 | Cycloalkyfused indole, benzothiophene, benzofuran and idene derivatives | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297704-B2 | Cycloalkyfused indole, benzothiophene, benzofuran and idene derivatives | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| WO-2007025892-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, HCCS, CFTR | CA1 4388/4885CA2 3789/4885CA9 963/4885 |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD17B1, HSD17B2, HSD3B2 | CA1 3958/4885CA2 3689/4885CA9 2897/4885 |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | CA1 4388/4885CA2 3789/4885CA9 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.